drugset / Trial / NCT02412644
Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis
Phase 4
Completed
29 enrolled
Psoriasis Treatment Center of Central New Jersey
Celgene Corporation · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
12 weeks open label with Otezla® and NUVB, followed by 6 month double blind Otezla® (apremilast) or placebo to subjects who obtain PASI 75 at week 12 of phototherapy
Timeline
- Start
- 2015-05-28
- Primary completion
- 2016-07
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Apremilast | Small molecule | 30 mg | — |